TGTX logo

TG Therapeutics (TGTX) Company Overview

Profile

Full Name:

TG Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 3, 2010

Indexes:

Not included

Website:

http://www.tgtherapeutics.com

Description:

TG Therapeutics (TGTX) is a biotechnology company focused on developing innovative treatments for cancer and autoimmune diseases. They specialize in targeted therapies that aim to improve patient outcomes and quality of life. Their research includes advanced drug candidates for various types of blood cancers and other conditions.

Key Details

Price

$35.05

Market Cap

$5.46 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$329.00 M(+40.80% YoY)

Annual EPS

$0.15(+66.67% YoY)

PE Ratio

-

Annual ROE

10.52%

Annual Debt To Equity

1.14

Beta

1.22

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 28, 2025

Recent annual earnings:

Feb 28, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 30, 2012

Analyst ratings

Recent major analysts updates

Jan 15, 25 HC Wainwright & Co.
Buy
Nov 25, 24 JP Morgan
Overweight
Nov 5, 24 HC Wainwright & Co.
Buy
Nov 5, 24 Goldman Sachs
Neutral
Oct 29, 24 TD Cowen
Buy
Sep 18, 24 HC Wainwright & Co.
Buy
Aug 7, 24 Goldman Sachs
Neutral
Aug 7, 24 B. Riley Securities
Buy
Aug 6, 24 HC Wainwright & Co.
Buy
May 2, 24 Ladenburg Thalmann
Buy

Screeners with TGTX included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Best performing stocks last 5 years
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$35.05
TGTX price is $35.05

Price All-time High

$233.44
TGTX price is currently -84.99% below its historical high of $233.44

Price Analysts Target

$46.00
TGTX price is currently -23.80% lower than the consensus analysts' forecast

Price Most Recent Change

-2.5%
TGTX price was down -2.5% on Mar 6, 2025

Price YTD Change

+16.83%
TGTX price is up +16.83% since January 1st

Price 3-Year Change

+299.66%
TGTX price is up +299.66% over the past 3 years

Market cap

Market Cap

$5.46 B
TGTX market capitalization is $5.46 billion

Market Cap 3-Year Change

+335.61%
TGTX market capitalization is up +335.61% over the past 3 years

Market Cap All-time High

$7.63 B
TGTX market capitalization is currently -28.52% below its historical high of $7.63 billion

Market Cap Sector Rank

89.05%
TGTX market capitalization is higher than 89.05% of companies in Healthcare sector

Technical

Beta

1.22
TGTX beta is 1.22

200-day SMA

$25.20
TGTX price is currently +39.07% above its 200-day simple moving average

14-day RSI

65.06
TGTX 14-day relative strength index is 65.06

30-day Relative Volume

1.05
TGTX 30-day relative volume is 1.05

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$329.00 M
TGTX annual revenue is $329.00 million

Annual Revenue Analysts Estimate

$560.29 M
TGTX annual revenue is currently -41.28% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+40.8%
TGTX annual revenue is up +40.8% year-on-year

Annual Revenue Sector Rank

71.02%
TGTX annual revenue is higher than 71.02% of companies in Healthcare sector

Profit

Annual Gross Profit

$290.52 M
TGTX annual gross profit is $290.52 million

Annual Gross Margin

88.30%
TGTX annual gross profit margin is 88.30%

Annual Operating Profit

$41.93 M
TGTX annual operating income is $41.93 million

Annual Operating Margin

12.74%
TGTX annual operating profit margin is 12.74%

Annual Net Income

$23.38 M
TGTX annual net profit is $23.38 million

Annual Net Margin

-
TGTX annual net profit margin value is unknown

EPS

Annual EPS

$0.15
TGTX annual earnings per share is $0.15

Annual EPS Analysts Estimate

$1.05
TGTX annual earnings per share is currently -85.78% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+66.67%
TGTX annual earnings per share is up +66.67% year-on-year

Annual EPS Sector Rank

84.2%
TGTX annual earnings per share is higher than 84.2% of companies in Healthcare sector

ROA & ROE

Annual ROA

4.05%
TGTX annual return on assets is 4.05%

Annual ROE

10.52%
TGTX annual return on equity is 10.52%

EBIT & EBITDA

Annual EBIT

$49.62 M
TGTX annual earnings before interest & taxes is $49.62 million

Annual EBITDA

$49.90 M
TGTX annual EBITDA is $49.90 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
TGTX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
TGTX price to earnings ratio is unknown

PB Ratio

PB Ratio

24.54
TGTX price to book ratio is 24.54

PB Ratio Sector Rank

96.86%
TGTX price to book ratio is higher than 96.86% of companies in Healthcare sector

PS Ratio

PS Ratio

16.58
TGTX price to sales ratio is 16.58

PS Ratio Sector Rank

82.99%
TGTX price to sales ratio is higher than 82.99% of companies in Healthcare sector

Enterprise value

Enterprise Value

$5.53 B
TGTX enterprise value is $5.53 billion

Enterprise Value Sector Rank

88.37%
TGTX enterprise value is higher than 88.37% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

110.67
TGTX EV/EBITDA is 110.67

EV/EBITDA Sector Rank

98.85%
TGTX EV/EBITDA is higher than 98.85% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

6.25
TGTX annual current ratio is 6.25

Annual Quick Ratio

5.03
TGTX annual quick ratio is 5.03

Leverage

Annual Debt To Equity

1.14
TGTX annual debt to equity ratio is 1.14

Annual Interest Coverage Ratio

2.07
TGTX annual interest coverage ratio is 2.07

Risk & Stability

Piotroski F-Score

4
TGTX piotroski f-score is 4

Altman Z-Score

7.35
TGTX altman z-score is 7.35

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$577.69 M
TGTX annual total assets is $577.69 million

Annual Non Current Assets

$11.33 M
TGTX annual long term assets is $11.33 million

Annual Current Assets

$566.36 M
TGTX annual total current assets is $566.36 million

Annual Cash & Cash Equivalents

$179.89 M
TGTX annual cash & cash equivalents is $179.89 million

Equity

Annual Book Value

$222.36 M
TGTX annual book value is $222.36 million

Annual Working Capital

$475.68 M
TGTX annual working capital is $475.68 million

Liabilities

Annual Total Liabilities

$355.33 M
TGTX annual total liabilities is $355.33 million

Annual Total Long Term Liabilities

$264.65 M
TGTX annual total long term liabilities is $264.65 million

Annual Current Liabilities

$90.68 M
TGTX annual total current liabilities is $90.68 million

Annual Accounts Payable

-
TGTX annual accounts payable value is unknown

Debt

Annual Total Debt

$253.72 M
TGTX annual total debt is $253.72 million

Annual Total Debt 1-Year Change

+129%
TGTX annual total debt is up +129% year-on-year

Annual Long Term Debt

$252.56 M
TGTX annual long term debt is $252.56 million

Annual Short Term Debt

-
TGTX annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$287.07 M
TGTX annual total expenses is $287.07 million

Annual Operating Expenses

$248.59 M
TGTX annual total operating expenses is $248.59 million

Annual Cost Of Goods Sold

$38.49 M
TGTX annual cost of goods sold is $38.49 million

Annual SGA

$154.30 M
TGTX annual SGA is $154.30 million

Annual D&A

$280.00 K
TGTX annual depreciation & amortization is $280.00 thousand

Annual Interest Expense

$24.03 M
TGTX annual interest expense is $24.03 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$40.52 M
TGTX annual cash flow from operations is -$40.52 million

Annual CFO 1-Year Change

-28.98%
TGTX annual cash flow from operations is down -28.98% year-on-year

Annual CFI

-$1.04 M
TGTX annual cash flow from investing activities is -$1.04 million

Annual CFI 1-Year Change

+97.95%
TGTX annual cash flow from investing activities is up +97.95% year-on-year

Annual CFF

$128.53 M
TGTX annual cash flow from financing activities is $128.53 million

Annual CFF 1-Year Change

+76.78%
TGTX annual cash flow from financing activities is up +76.78% year-on-year

Free CashFlow

Annual FCF

-$40.56 M
TGTX annual free cash flow is -$40.56 million

Annual FCF 1-Year Change

-29.12%
TGTX annual free cash flow is down -29.12% year-on-year

CAPEX

Annual CAPEX

$45.00 K
TGTX annual capital expenditures is $45.00 thousand

Annual CAPEX 1-Year Change

-
TGTX annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

BLCO logo
Bausch Lomb (BLCO)
GH logo
Guardant Health (GH)
ELAN logo
Elanco Animal Health Incorporated (ELAN)
IONS logo
Ionis Pharmaceuticals (IONS)
INSP logo
Inspire Medical Systems (INSP)
STVN logo
Stevanato Group SpA (STVN)
OPCH logo
Option Care Health (OPCH)
KRYS logo
Krystal Biotech (KRYS)
ALKS logo
Alkermes (ALKS)

FAQ

  • What is the ticker symbol for TG Therapeutics?
  • Does TG Therapeutics pay dividends?
  • What sector is TG Therapeutics in?
  • What industry is TG Therapeutics in?
  • What country is TG Therapeutics based in?
  • When did TG Therapeutics go public?
  • Is TG Therapeutics in the S&P 500?
  • Is TG Therapeutics in the NASDAQ 100?
  • Is TG Therapeutics in the Dow Jones?
  • When was TG Therapeutics's last earnings report?
  • When does TG Therapeutics report earnings?
  • Should I buy TG Therapeutics stock now?

What is the ticker symbol for TG Therapeutics?

The ticker symbol for TG Therapeutics is NASDAQ:TGTX

Does TG Therapeutics pay dividends?

No, TG Therapeutics does not pay dividends

What sector is TG Therapeutics in?

TG Therapeutics is in the Healthcare sector

What industry is TG Therapeutics in?

TG Therapeutics is in the Biotechnology industry

What country is TG Therapeutics based in?

TG Therapeutics is headquartered in United States

When did TG Therapeutics go public?

TG Therapeutics's initial public offering (IPO) was on May 3, 2010

Is TG Therapeutics in the S&P 500?

No, TG Therapeutics is not included in the S&P 500 index

Is TG Therapeutics in the NASDAQ 100?

No, TG Therapeutics is not included in the NASDAQ 100 index

Is TG Therapeutics in the Dow Jones?

No, TG Therapeutics is not included in the Dow Jones index

When was TG Therapeutics's last earnings report?

TG Therapeutics's most recent earnings report was on Feb 28, 2025

When does TG Therapeutics report earnings?

The date for TG Therapeutics's next earnings report has not been announced yet

Should I buy TG Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions